Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion.

Abstract

OBJECTIVE:

To investigate Botulinum toxin type B (BNT-B) injection's effect and duration depending on dose for patients with brain lesion.

METHOD:

Twenty one patients with brain lesion and severe drooling were included and divided into three groups. All patients received conventional dysphagia therapy. Group A patients (n=7) received an injection of 1,500 units and group B patients (n=7) received an injection of 2,500 units of BNT-B in submandibular gland under ultrasound guidance. Group C patients (n=7) received conventional dysphagia therapy. Saliva secretion was assessed quantitatively at baseline and at weeks 1, 2, 4, 8, and 12. The severity and frequency of drooling was assessed using the Drooling Quotient (DQ) by patients and/or caregivers.

RESULTS:

Group A and B reported a distinct improvement of the symptoms within 2 weeks after BNT-B injection. Compared to the baseline, the mean amount of saliva decreased significantly throughout the study. However, there was no meaningful difference between the two groups. The greatest reductions were achieved at 2 weeks and lasted up to 8 weeks after BNT-B injection. Group C did not show any differences.

CONCLUSION:

Local injection of 1,500 units of BNT-B into salivary glands under ultrasonic guidance proved to be a safe and effective dose for drooling in patient with brain lesion, as did 2,500 units.

• Authors: Hee Dong Park, Hyo Jae Kim, Sang Jun Park, Yong Min Choi
• Journal: Annals of rehabilitation medicine (Ann Rehabil Med) Vol. 36 Issue 6 Pg. 841-8 (Dec 2012) ISSN: 2234-0645 [Print] Korea (South)
• PMID: 23342318 (Publication Type: Journal Article)